Cargando…

Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients

DNA damage response (DDR) molecules are protective against genotoxic stresses. DDR molecules are also involved in the survival of cancer cells in patients undergoing anti-cancer therapies. Therefore, DDR molecules are potential markers of cancer progression in addition to being potential therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyoung Min, Moon, Young Jae, Park, See-Hyoung, Park, Hye Jeong, Wang, Sung Il, Park, Ho Sung, Lee, Ho, Kwon, Keun Sang, Moon, Woo Sung, Lee, Dong Geun, Kim, Jung Ryul, Jang, Kyu Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028069/ https://www.ncbi.nlm.nih.gov/pubmed/27643881 http://dx.doi.org/10.1371/journal.pone.0163193

Ejemplares similares

Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients()
por: Park, See-Hyoung, et al.
Publicado: (2015)

A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients
por: Seong, Moon-Woo, et al.
Publicado: (2014)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients
por: Kim, Hee Nam, et al.
Publicado: (2019)

Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study
por: Son, Byung Ho, et al.
Publicado: (2012)

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
por: Lee, Anbok, et al.
Publicado: (2020)

DBC1/CCAR2 is involved in the stabilization of androgen receptor and the progression of osteosarcoma
por: Wagle, Sajeev, et al.
Publicado: (2015)

Prevalence of BRCA1 and BRCA2 Mutations in Korean Breast Cancer Patients
por: Ahn, Sei Hyun, et al.
Publicado: (2004)

Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer
por: Kim, Hee Sung, et al.
Publicado: (2019)

The Expression Patterns of FAM83H and PANX2 Are Associated With Shorter Survival of Clear Cell Renal Cell Carcinoma Patients
por: Kim, Kyoung Min, et al.
Publicado: (2019)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
por: Kim, Joo Heung, et al.
Publicado: (2021)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients
por: Yoon, Kyong-Ah, et al.
Publicado: (2017)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas
por: Bae, Jun Sang, et al.
Publicado: (2017)

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer
por: Kim, Haeyoung, et al.
Publicado: (2013)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Author Correction: Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
por: Kim, Joo Heung, et al.
Publicado: (2023)

Performance evaluation of an amplicon‐based next‐generation sequencing panel for BRCA1 and BRCA2 variant detection
por: Park, Kuenyoul, et al.
Publicado: (2020)

Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls
por: Park, Ji Soo, et al.
Publicado: (2017)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Comparison of Ion Personal Genome Machine Platforms for the Detection of Variants in BRCA1 and BRCA2
por: Hwang, Sang Mee, et al.
Publicado: (2018)

Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
por: Park, Joonhong, et al.
Publicado: (2016)

Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Prediction of carrying a BRCA1 or BRCA2 mutation
por: Lee, Kyung-Hun
Publicado: (2023)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland
por: Kim, Sun Eui, et al.
Publicado: (2018)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea
por: Kim, Do-Hoon, et al.
Publicado: (2017)

Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
por: Jung, Sung Mi, et al.
Publicado: (2020)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients
por: Park, Boyoung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h6cn9qvnksksbo1re34008j64f